印度代购提示您，本品历经近很多年的操作说明最新型的免疫疗法对许多恶性肿瘤是很有效果的，并且整体来说不良反应也相对比较小。现在免疫检查点抑制剂的可用的恶性肿瘤类型也是比较多的，例如纳武单抗能够适用于晚期黑色素肿瘤、晚期鳞状非小细胞肺癌、直肠癌、晚期非小细胞肺癌、晚期肾细胞癌、头颈鳞癌和晚期尿路上皮癌等。

 The operation of this product over recent years indicates that the latest immunotherapy is very effective in many malignancies, and the overall adverse reactions are relatively small. Currently, there are many types of malignancies available with immune checkpoint inhibitors. For example, Navumab can be applied to advanced melanoma, advanced squamous non-small cell lung cancer, rectal cancer, advanced non-small cell lung cancer, advanced renal cell carcinoma, head and neck squamous cell carcinoma, and advanced urothelial carcinoma.

纳武单抗、纳武利尤单抗

　　印度代购提示您，本品纳武单抗是一种程序性死亡（PD-1）抑制剂，可帮助您的免疫系统T细胞识别并攻击癌细胞。它通过帮助阻止癌细胞伪装自身和逃避免疫系统检测的能力来做到这一点。

　　印度代购提示您，本品像纳武单抗这样的免疫疗法，即使病情有所好转，最初看起来也像癌症在发展。这被称为“伪进展”，其导致肿瘤尺寸的短期增加或新肿瘤的出现，随后延迟了肿瘤的缩小，在用免疫治疗时，医生会随时监测患者的情况，患者也可以定期进行CT（计算机断层扫描）和PET（正电子发射断层扫描）扫描以及MRI（磁共振成像）。这些测试有助于确定肿瘤大小是否正在改变。

As a reminder, immunotherapies such as Navumab, even when improved, at first appear to be developing cancer. This is called "progress", its lead to the emergence of new short-term increase in tumor size or tumor, then delayed tumor reduction, when treated with immune, doctors can monitor patients at any time, patients can also regular CT (computed tomography) and PET (positron emission tomography) scan and MRI (magnetic resonance imaging). These tests help determine whether the tumor size is changing.